drugset / Trial / NCT00291447
111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this clinical trial is to describe the toxicity, biodistribution, pharmacokinetics and tumour uptake of a single infusion of ch806 (tagged with a trace amount of radioactive 111-Indium: 111In-ch806) in patients with advanced tumours expressing the 806 antigen.
Timeline
- Start
- 2005-05
- Primary completion
- 2006-02-16
- Completion
- 2006-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ch806 | Monoclonal antibody | 5 mg/m2 | Intravenous |
| Subject | ch806 | Monoclonal antibody | 10 mg/m2 | Intravenous |
| Subject | ch806 | Monoclonal antibody | 20 mg/m2 | Intravenous |
| Subject | ch806 | Monoclonal antibody | 40 mg/m2 | Intravenous |